Explore All 3116 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | April 3, 2013 |
| Target | AlphaCore Pharma |
| Sector | Life Science |
| Buyer(s) | MedImmune |
| Deal Type | Add-on Acquisition |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1988 |
| Sector | Medical Products |
| Employees | 2,000 |
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland.
| Deal Context for Buyer | # |
|---|---|
| Overall | 3 of 6 |
| Sector: Life Science | 3 of 6 |
| Type: Add-on Acquisition | 3 of 5 |
| State: Michigan | 1 of 1 |
| Country: United States | 3 of 4 |
| Year: 2013 | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-09-14 |
Cellective Therapeutics
Gaithersburg, Maryland, United States Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, Crohn?s disease and rheumatoid arthritis. The Company was founded in 2003 by Dr. Tom Tedder, Chairman of the Department of Immunology at Duke University, and based on technology licensed from Duke University and the Dana Farber Cancer Institute. Cellective was acquired by MedImmune in September of 2005. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-26 |
Amplimmune
Gaithersburg, Maryland, United States Amplimmune, Inc. is a biologics company focused on developing novel therapeutics in cancer immunology. |
Buy | $500M |
